当前位置:
X-MOL 学术
›
J. Hepatol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Reply to “Immune checkpoint inhibitor therapy for functional cure of hepatitis B in cancer patients: a promising strategy?” and “Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B”
Journal of Hepatology ( IF 26.8 ) Pub Date : 2024-11-08 , DOI: 10.1016/j.jhep.2024.10.045 Hsien-Chen Mon, Yi-Hsiang Huang
中文翻译:
回复 “免疫检查点抑制剂治疗癌症患者乙型肝炎功能性治愈:一种有前途的策略?”和“肝细胞癌患者是乙型肝炎免疫检查点抑制剂的理想研究人群”
这封信没有收到任何财政支持。
作者声明,他们没有已知的竞争性经济利益或个人关系,这些利益或个人关系似乎可能会影响本文报告的工作。
HCM:手稿起草;YHH:手稿的批判性专家审查和修订。
没有其他鸣谢。
更新日期:2024-11-09
Journal of Hepatology ( IF 26.8 ) Pub Date : 2024-11-08 , DOI: 10.1016/j.jhep.2024.10.045 Hsien-Chen Mon, Yi-Hsiang Huang
Section snippets
Financial disclosure funding
No financial support was received for this letter.Funding funding
NoneConflict-of-interest statement COI
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Author contributions author-disclosure
HCM: manuscript drafting; YHH: critical expert review and revision of the manuscript.Acknowledgements
There are no additional acknowledgements.中文翻译:
回复 “免疫检查点抑制剂治疗癌症患者乙型肝炎功能性治愈:一种有前途的策略?”和“肝细胞癌患者是乙型肝炎免疫检查点抑制剂的理想研究人群”
部分片段
财务披露资金
这封信没有收到任何财政支持。
资金 资助
没有
利益冲突声明 COI
作者声明,他们没有已知的竞争性经济利益或个人关系,这些利益或个人关系似乎可能会影响本文报告的工作。
作者贡献 作者披露
HCM:手稿起草;YHH:手稿的批判性专家审查和修订。
确认
没有其他鸣谢。